Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05293756 · ClinicalTrials.gov registry record · NA

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

A NA study of Hypertension and Quality of Life, sponsored by Case Western Reserve University.

Recruiting
Registry status
NA
Development phase
208
Enrollment target
1
Study location

NCT05293756 is a NA study of Hypertension and Quality of Life that is actively recruiting participants, run by Case Western Reserve University. The registered enrollment target is 208 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05293756, a NA study of Hypertension and Quality of Life, is actively recruiting participants, sponsored by Case Western Reserve University.

RECRUITING
Registry status
NA
Development phase
208 participants
Enrollment target
1
Study location

Study Summary

Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as well as a risk factor for the incidence of stroke, diabetes, chronic kidney disease, and dementia. Importantly, older adults account for 15% of the U.S. population, and two-thirds of older adults over age 60 have HTN, with higher rates observed in AA older adults. Strategies to support self-managing HTN and BP control are crucial as the older population is projected to age considerably and become more racially and ethnically diverse. Research has documented the negative effects on health and health outcomes of poorly controlled BP and is one of the most important modifiable CVD risk factors. Lower BP targets will require aggressive management and an increase in antihypertensive medications. Therefore, to achieve lower targets in this population, greater efforts, including patient-centered methods will be needed to support self-managing HTN, especially in terms of medication adherence. As we shifted into the digital age, the use of mHealth technologies (smart phones, applications, SMS or text messaging) has been a powerful approach and mechanism for the treatment and management of chronic diseases. However, behavioral interventions that incorporate technology do not reach minorities or disadvantaged AA older adults with HTN. OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) will leverage existing knowledge of effective technology-based components for HTN self-management to support and improve BP control using unique aspects of mHealth platforms in AA older adults. Findings from this study, if confirmed, will improve BP control and support self-managing HTN, as well as has the potential to close the health disparity gap between AA and non-AA

Interventions

  • BEHAVIORAL OPTIMA-BP Intervention

Study Locations (1)

Ohio

  • Case Western Reserve University - Cleveland

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2021-02-14
Est. Completion 2027-05-31
Phase NA

Sponsor

Case Western Reserve University

141 total trials

What the Registry Record Tells You About NCT05293756

The ClinicalTrials.gov registry entry for NCT05293756 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which OPTIMA-BP Intervention is the first listed.

NCT05293756 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05293756 about?

NCT05293756 is a clinical study titled "OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)". Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as...

What is the current status of trial NCT05293756?

This trial is currently recruiting. It is a NA study. The enrollment target is 208 participants. The study started on 2021-02-14. Estimated completion is 2027-05-31.

What conditions does trial NCT05293756 study?

This clinical trial studies the following conditions: Hypertension, Quality of Life, Self-management, Technology.

What interventions are being tested in trial NCT05293756?

The interventions under investigation include: OPTIMA-BP Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05293756?

This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05293756 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.